Loading...
JW (Cayman) Therapeutics Co. Ltd
2126.HK•HKSE
Healthcare
Biotechnology
HK$4.85
HK$-0.34(-6.55%)

JW (Cayman) Therapeutics Co. Ltd (2126.HK) Balance Sheet Analysis
JW (Cayman) Therapeutics Co. Ltd (2126.HK) manages its money wisely, with plenty of N/A and N/A to cover its bills. The company’s long-term debts are manageable, balanced by steady -373.30%. Shareholders’ stake in the business has shrunk. Overall, the numbers show a cautious position, giving it room to invest, expand, or adapt. For investors, this paints a risky picture for the future.Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan